Literature DB >> 19759093

Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting.

Meikei Leung1, Charlton Cheung, Kevin Yu, Benjamin Yip, Pak Sham, Qi Li, Siew Chua, Grainne McAlonan.   

Abstract

BACKGROUND: Cerebral morphological abnormalities in schizophrenia may be modulated by treatment, chronicity, and duration of illness. Comparing brain imaging studies of individuals with first-episode schizophrenia and neuroleptic naive (NN-FES) with that of their neuroleptic-treated counterparts (NT-FES) can help to dissect out the effect of these potential confounders.
METHODS: We used the anatomical likelihood estimation method to compare voxel-based morphometric studies of NN-FES (n = 162 patients) and NT-FES (n = 336 patients) studies. The analysis included a sample size weighting step based on the Liptak-Stouffer method to reflect the greater power of larger studies.
RESULTS: Patient samples were matched for age, gender, and duration of illness. An extensive network of gray matter deficits in frontal, temporal, insular, striatal, posterior cingulate, and cerebellar regions was detected in the NN-FES samples as compared with healthy controls. Major deficits were detected in the frontal, superior temporal, insular, and parahippocampal regions for the NT-FES group compared with the NN-FES group. In addition, the NT-FES group showed minor deficits in the caudate, cingulate, and inferior temporal regions compared with the NN-FES group. There were no regions with gray matter volumetric excess in the NT-FES group.
CONCLUSION: Frontal, striato-limbic, and temporal morphological abnormalities are present in the early stage of schizophrenia and are unrelated to the effects of neuroleptic treatment, chronicity, and duration of illness. There may be dynamic effects of treatment on striato-limbic and temporal, but not frontal, regional gray matter volumes of the brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759093      PMCID: PMC3004197          DOI: 10.1093/schbul/sbp099

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  97 in total

1.  Meta-analysis of the functional neuroanatomy of single-word reading: method and validation.

Authors:  Peter E Turkeltaub; Guinevere F Eden; Karen M Jones; Thomas A Zeffiro
Journal:  Neuroimage       Date:  2002-07       Impact factor: 6.556

2.  Progressive brain volume loss during adolescence in childhood-onset schizophrenia.

Authors:  Alexandra L Sporn; Deanna K Greenstein; Nitin Gogtay; Neal O Jeffries; Marge Lenane; Peter Gochman; Liv S Clasen; Jonathan Blumenthal; Jay N Giedd; Judith L Rapoport
Journal:  Am J Psychiatry       Date:  2003-12       Impact factor: 18.112

3.  Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment.

Authors:  Beth E Snitz; Angus MacDonald; Jonathan D Cohen; Raymond Y Cho; Theresa Becker; Cameron S Carter
Journal:  Am J Psychiatry       Date:  2005-12       Impact factor: 18.112

4.  Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine.

Authors:  M H Chakos; J A Lieberman; J Alvir; R Bilder; M Ashtari
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

5.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs.

Authors:  M H Chakos; J A Lieberman; R M Bilder; M Borenstein; G Lerner; B Bogerts; H Wu; B Kinon; M Ashtari
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

6.  Focal gray matter density changes in schizophrenia.

Authors:  H E Hulshoff Pol; H G Schnack; R C Mandl; N E van Haren; H Koning; D L Collins; A C Evans; R S Kahn
Journal:  Arch Gen Psychiatry       Date:  2001-12

7.  Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia.

Authors:  K M R Prasad; B H Shirts; R H Yolken; M S Keshavan; V L Nimgaonkar
Journal:  Mol Psychiatry       Date:  2006-10-10       Impact factor: 15.992

8.  Progressive grey matter atrophy over the first 2-3 years of illness in first-episode schizophrenia: a tensor-based morphometry study.

Authors:  Thomas J Whitford; Stuart M Grieve; Tom F D Farrow; Lavier Gomes; John Brennan; Anthony W F Harris; Evian Gordon; Leanne M Williams
Journal:  Neuroimage       Date:  2006-05-03       Impact factor: 6.556

9.  Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.

Authors:  James L Reilly; Margret S H Harris; Matcheri S Keshavan; John A Sweeney
Journal:  Arch Gen Psychiatry       Date:  2006-11

10.  Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?

Authors:  T J Crow; A J Cross; E C Johnstone; F Owen; D G Owens; J L Waddington
Journal:  J Clin Psychopharmacol       Date:  1982-10       Impact factor: 3.153

View more
  51 in total

Review 1.  Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis.

Authors:  Paolo Fusar-Poli
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

2.  The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation.

Authors:  Katja Karg; Margit Burmeister; Kerby Shedden; Srijan Sen
Journal:  Arch Gen Psychiatry       Date:  2011-01-03

3.  Picturing neuroscience research through a human rights lens: imaging first-episode schizophrenic treatment-naive individuals.

Authors:  Marleen Eijkholt; James A Anderson; Judy Illes
Journal:  Int J Law Psychiatry       Date:  2012-02-02

4.  Gray matter volume alterations in first-episode drug-naïve patients with deficit and nondeficit schizophrenia.

Authors:  Wei Lei; Wei Deng; Mingli Li; Zongling He; Yuanyuan Han; Chaohua Huang; Xiaohong Ma; Qiang Wang; Wanjun Guo; Yinfei Li; Lijun Jiang; Qiyong Gong; Xun Hu; Nanyin Zhang; Tao Li
Journal:  Psychiatry Res       Date:  2015-09-11       Impact factor: 3.222

5.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 6.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

7.  Shared intermediate phenotypes for schizophrenia and bipolar disorder: neuroanatomical features of subtypes distinguished by executive dysfunction.

Authors:  Alana M Shepherd; Yann Quidé; Kristin R Laurens; Nicole O'Reilly; Jesseca E Rowland; Philip B Mitchell; Vaughan J Carr; Melissa J Green
Journal:  J Psychiatry Neurosci       Date:  2015-01       Impact factor: 6.186

8.  A Prospective Longitudinal Investigation of Cortical Thickness and Gyrification in Schizophrenia.

Authors:  Eric A Nelson; Nina V Kraguljac; David M White; Ripu D Jindal; Ah L Shin; Adrienne C Lahti
Journal:  Can J Psychiatry       Date:  2020-02-05       Impact factor: 4.356

9.  Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.

Authors:  Nathan L Hutcheson; David G Clark; Mark S Bolding; David M White; Adrienne C Lahti
Journal:  Psychiatry Res       Date:  2013-10-22       Impact factor: 3.222

10.  Are Bipolar Disorder and Schizophrenia Neuroanatomically Distinct? An Anatomical Likelihood Meta-analysis.

Authors:  Kevin Yu; Charlton Cheung; Meikei Leung; Qi Li; Siew Chua; Gráinne McAlonan
Journal:  Front Hum Neurosci       Date:  2010-10-26       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.